MRK Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 32.71% compared to Merck &'s net margin of 19.72%. Merck &'s return on equity of 39.02% beat Gilead Sciences's return on equity of 32.29%.

Merck & has a consensus price target of $105.02, signalling upside risk potential of 38.24%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 18.71%. Given that Merck & has higher upside potential than Gilead Sciences, analysts believe Merck & is more attractive than Gilead Sciences.

Merck & has a beta of 0.429, which suggesting that the stock is 57.139% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 4.16%. Gilead Sciences offers a yield of 3.2% to investors and pays a quarterly dividend of $0.79 per share. Merck & pays 45.8% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Merck & quarterly revenues are $15.5B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Merck &'s net income of $5.1B is higher than Gilead Sciences's net income of $1.3B. Notably, Merck &'s price-to-earnings ratio is 11.06x while Gilead Sciences's PE ratio is 20.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.02x versus 4.25x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 32.71% compared to Merck &'s net margin of 50.24%. Merck &'s return on equity of 39.02% beat Johnson & Johnson's return on equity of 30.18%.

Merck & has a consensus price target of $105.02, signalling upside risk potential of 38.24%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 10.36%. Given that Merck & has higher upside potential than Johnson & Johnson, analysts believe Merck & is more attractive than Johnson & Johnson.

Merck & has a beta of 0.429, which suggesting that the stock is 57.139% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 4.16%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. Merck & pays 45.8% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Merck &'s net income of $5.1B is lower than Johnson & Johnson's net income of $11B. Notably, Merck &'s price-to-earnings ratio is 11.06x while Johnson & Johnson's PE ratio is 17.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.02x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 32.71% compared to Merck &'s net margin of 21.68%. Merck &'s return on equity of 39.02% beat Eli Lilly and's return on equity of 78.25%.

Merck & has a consensus price target of $105.02, signalling upside risk potential of 38.24%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Merck & has higher upside potential than Eli Lilly and, analysts believe Merck & is more attractive than Eli Lilly and.

Merck & has a beta of 0.429, which suggesting that the stock is 57.139% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 4.16%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Merck & pays 45.8% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are larger than Eli Lilly and quarterly revenues of $12.7B. Merck &'s net income of $5.1B is higher than Eli Lilly and's net income of $2.8B. Notably, Merck &'s price-to-earnings ratio is 11.06x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.02x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 32.71% compared to Merck &'s net margin of -907.48%. Merck &'s return on equity of 39.02% beat Moderna's return on equity of -29.23%.

Merck & has a consensus price target of $105.02, signalling upside risk potential of 38.24%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 93.66%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

Merck & has a beta of 0.429, which suggesting that the stock is 57.139% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 4.16%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are larger than Moderna quarterly revenues of $107M. Merck &'s net income of $5.1B is higher than Moderna's net income of -$971M. Notably, Merck &'s price-to-earnings ratio is 11.06x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.02x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.